ClinicalTrials.gg
CompletedNCT03822351COASTUpdated Oct 8, 2024Results posted

Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC

A Phase 2 interventional study of Durvalumab + Oleclumab and Durvalumab in Stage III Non-small Cell Lung Cancer and Unresectable, sponsored by MedImmune LLC. Completed at 73 sites in 9 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-10-08.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
189
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 37 under way, 11 of them phase 3. durvalumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
25th of 94
189 · median 74
Started
2018
with 7 others
Phase 2
58 of 94
11 open now
Registered
36th of 94
by date
Lead sponsor
4 of 94
MedImmune LLC

Among the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, this one is the 25th largest by enrollment, is one of 8 that started in 2018, is one of 58 in phase 2, and was the 36th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

16 of the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to compare the clinical activity of durvalumab alone vs durvalumab in combination with novel agents. The overall study goal is early identification of novel durvalumab combinations that are more active than durvalumab alone in the treatment of patients with unresectable, Stage III NSCLC who have not progressed after cCRT.

Read the detailed description

Study D9108C00001 (COAST) is a Phase 2, open-label, multicenter, randomized multidrug platform study assessing the efficacy and safety of durvalumab alone vs durvalumab in combination with novel agents in subjects with locally advanced, unresectable, Stage III non-small cell lung cancer (NSCLC).

03

Conditions studied

  • Stage III Non-small Cell Lung Cancer
  • Unresectable

Keywords

  • Locally Advanced NSCLC
  • Non-small Cell Lung Cancer
  • Cancer
  • Lung
  • Unresectable
  • Stage III
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  1. Written and any locally required authorization obtained from the subject prior to performing any protocol-related procedures, including screening evaluation
  2. Age 18 years or older
  3. Body weight ≥ 35 kg
  4. Subjects must have or cytologically documented NSCLC who present with locally advanced, unresectable, Stage III disease
  5. Subjects must have completed, without progressing, definitive cCRT within 42 days prior to being randomized into the study
  6. Provision of tumor tissue sample, when available, from original diagnosis obtained before initiation of chemoradiotherapy
  7. ≥ 12 weeks
  8. (ECOG) Performance Status of 0 or 1
  9. Subjects must have at least one previously irradiated tumor lesion that can be measured by v1.1

Main Exclusion Criteria:

  1. Mixed small cell and non-small cell lung cancer histology
  2. Current or prior use of medication within 14 days before the first dose of study drug
  3. Prior exposure to any anti-PD1, , or anti-CTLA4 antibody for treatment of NSCLC
  4. Subjects with history of ≥ Grade 2 pneumonitis from prior chemoradiation therapy
  5. Subjects with a history of venous thrombosis within the past 3 months
  6. Subjects with history of myocardial infarction, , or stroke in the past 6 months
  7. Congestive heart failure
  8. Active or prior documented or inflammatory disorders
  9. History of active primary immunodeficiency
  10. Active infection including tuberculosis, , , or (HIV)
  11. History of allogenic organ transplantation
  12. interval ≥ 470 ms
  13. History of another primary
  14. Concurrent enrollment in another clinical study [concurrent enrollment in an observational (non-interventional) clinical study or during the follow-up period of an interventional study is permitted]
  15. Females who are pregnant, lactating, or intend to become pregnant during their participation in the study
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
189 participants (actual)

Study arms

  • Experimental
    Control Arm (Durvalumab monotherapy)

    durvalumab IV

    Drug: Durvalumab

  • Experimental
    Arm A (durvalumab + oleclumab):

    durvalumab IV and oleclumab IV

    Drug: Durvalumab + Oleclumab

  • Experimental
    Arm B (durvalumab + monalizumab)

    durvalumab IV and monalizumab IV

    Drug: Durvalumab + Monalizumab

Interventions

  • DrugDurvalumab + Oleclumab

    Drug pages: Durvalumab · Oleclumab

    Durvalumab + Oleclumab

    Also known as: Durvalumab (MEDI-4736), Oleclumab (MEDI-9447)

  • Durvalumab

    Also known as: Durvalumab (MEDI-4736)

  • DrugDurvalumab + Monalizumab

    Drug pages: Durvalumab · Monalizumab

    Durvalumab + Monalizumab

    Also known as: Durvalumab (MEDI-4736), Monalizumab (IPH2201)

06

What researchers measure

Primary outcomes

  1. Objective Response (OR) Rate as a Measure of Antitumor Activity of Durvalumab Alone vs Durvalumab in Combination With Novel Agents

    ORR was defined as the percentage of participants with at least one visit response of Complete Response (CR) or Partial Response (PR) per RECIST 1.1 for target lesions: CR: Disappearance of all target lesions; PR: \>=30% decrease in the sum of the longest diameter of target lesions; OR = CR + PR.

    Time frame: ORR at 16 weeks after randomization is the timing for radiologic assessment of the primary endpoint

Secondary outcomes

  1. Presence of Adverse Events as a Measure of Safety and Tolerability of Durvalumab Alone and in Combination With Novel Agents

    The secondary endpoint of safety as assessed by the presence of adverse events and serious adverse events

    Time frame: From time of signature of informed consent up to 15 months post the first dose of study treatment

  2. Presence of Clinically Significant Laboratory Values as a Measure of Safety and Tolerability of Durvalumab Alone and in Combination With Novel Agents

    The secondary endpoint of safety as assessed by the presence of Grade 3 or 4 clinical laboratory toxicities (based on NCI-CTCAE v5.0) in chemistry and hematology values

    Time frame: From baseline up to 15 months post the first dose of study treatment

  3. Presence of Abnormalities in Vital Signs as a Measure of Safety and Tolerability of Durvalumab Alone and in Combination With Novel Agents

    The secondary endpoint of safety as assessed by the presence of abnormal vital signs reported as adverse events

    Time frame: From baseline up to 15 months post the first dose of study treatment

  4. Duration of Response (DoR) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents

    The duration from the first documentation of a subsequently confirmed OR to the first documentation of a disease progression according to RECIST v1.1 or death due to any cause, whichever occurs first. Only participants who have achieved OR (confirmed CR or confirmed PR) will be evaluated for DoR

    Time frame: Up to approximately 54 months (through the database cutoff date of 18-Jul-2023).

  5. Disease Control (DC) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents

    Disease control rate (DCR) was defined as the percentage of participants with a BOR of confirmed CR, confirmed PR, or SD (maintained for ≥ 16 weeks) based on RECIST v1.1.

    Time frame: Up to approximately 54 months (through the database cutoff date of 18-Jul-2023).

  6. Progression-Free Survival (PFS) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents

    PFS was defined as the time from randomization until the first documentation of disease progression according to RECIST v1.1 or death due to any cause, whichever occurs first

    Time frame: Up to approximately 54 months (through the database cutoff date of 18-Jul-2023).

  7. Progression-Free Survival 12 Month Landmark Rate (PFS-12) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents

    PFS-12 was defined as the percentage of participants who were alive and progression free at 12 months after randomization.

    Time frame: PFS rate at 12 months after randomization.

  8. Overall Survival (OS) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents

    OS was defined as the time from the date of randomization until death due to any cause.

    Time frame: From time of randomization until death due to any cause. Assessed through the database cutoff date of 18-Jul-2023).

  9. Pharmacokinetics of Durvalumab Alone and in Combination With Novel Agents

    Geometric mean serum concentrations of durvalumab (μg/mL) were reported for each time point where data warrant, as appropriate.

    Time frame: From randomization up to 15 months after first treatment: Cycle 1 Day 1 pre-dose and at end of infusion, Cycle 2 Day 1 pre-dose (1 month), Cycle 7 Day 1 pre-dose (6 months), Cycle 11 Day 1 pre-dose (10 months) and 15 months post Cycle 1 Day 1

  10. Pharmacokinetics of Novel Agents in Combination With Durvalumab

    Geometric mean serum concentrations of oleclumab (μg/mL) and monalizumab (μg/mL) were reported for each time point where data warrant, as appropriate.

    Time frame: From randomization up to 15 months after first treatment: Cycle 1 Day 1 pre-dose and at end of infusion, Cycle 2 Day 1 pre-dose (1 month), Cycle 7 Day 1 pre-dose (6 months), Cycle 11 Day 1 pre-dose (10 months) and 15 months post Cycle 1 Day 1

  11. Presence of Detectable Anti-Drug Antibody (ADA) Response to Durvalumab Alone and in Combination With Novel Agents

    ADA prevalence was defined as the percentage of participants with positive ADA result at any time, baseline or post-baseline. ADA positive post-baseline only was also referred to as treatment-induced ADA positive. Treatment-boosted ADA was defined as baseline positive ADA titer that was boosted to a 4-fold or higher following drug administration. Persistently positive was defined as positive at ≥2 post-baseline assessments (with ≥16 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive was defined as having at least 1 post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive. ADA incidence (treatment-emergent ADA positive) was defined as the sum of treatment-induced ADA and treatment-boosted ADA.

    Time frame: From randomization up to 15 months after first treatment: Cycle 1 Day 1 pre-dose, Cycle 2 Day 1 pre-dose (1 month), Cycle 7 Day 1 pre-dose (6 months), Cycle 11 Day 1 pre-dose (10 months) and 15 months post Cycle 1 Day 1

  12. Presence of Detectable Anti-Drug Antibody (ADA) Response to Novel Agents in Combination With Durvalumab

    ADA prevalence was defined as the percentage of participants with positive ADA result at any time, baseline or post-baseline. ADA positive post-baseline only was also referred to as treatment-induced ADA positive. Treatment-boosted ADA was defined as baseline positive ADA titer that was boosted to a 4-fold or higher following drug administration. Persistently positive was defined as positive at ≥2 post-baseline assessments (with ≥16 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive was defined as having at least 1 post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive. ADA incidence (treatment-emergent ADA positive) was defined as the sum of treatment-induced ADA and treatment-boosted ADA.

    Time frame: From randomization up to 15 months after first treatment: Cycle 1 Day 1 pre-dose, Cycle 2 Day 1 pre-dose (1 month), Cycle 7 Day 1 pre-dose (6 months), Cycle 11 Day 1 pre-dose (10 months) and 15 months post Cycle 1 Day 1

07

Results

Posted Oct 8, 2024

Participant flow

The first participant was randomized into the study on 3 January 2019 and the last participant was randomized on 6 July 2020.

Participant flow — Overall Study
MilestoneControl Arm (Durvalumab Monotherapy)Arm A (Durvalumab + Oleclumab)Arm B (Durvalumab + Monalizumab)
Started676062
Completed212930
Not completed463132
Withdrew: Death272324
Withdrew: Lost to follow-up621
Withdrew: Withdrawal by subject1046
Withdrew: Progressive disease210
Withdrew: Not treated111

Outcome measures

PrimaryObjective Response (OR) Rate as a Measure of Antitumor Activity of Durvalumab Alone vs Durvalumab in Combination With Novel Agents

ORR was defined as the percentage of participants with at least one visit response of Complete Response (CR) or Partial Response (PR) per RECIST 1.1 for target lesions: CR: Disappearance of all target lesions; PR: \>=30% decrease in the sum of the longest diameter of target lesions; OR = CR + PR.

Time frame:
ORR at 16 weeks after randomization is the timing for radiologic assessment of the primary endpoint
Reported as:
Number · Percentage of Participants
Objective Response (OR) Rate as a Measure of Antitumor Activity of Durvalumab Alone vs Durvalumab in Combination With Novel Agents
Percentage of ParticipantsControl Arm (Durvalumab Monotherapy)Arm A (Durvalumab + Oleclumab)Arm B (Durvalumab + Monalizumab)
Objective Response (OR) Rate as a Measure of Antitumor Activity of Durvalumab Alone vs Durvalumab in Combination With Novel Agents23.9 (14.3 to 35.9)35.0 (23.1 to 48.4)40.3 (28.1 to 53.6)
SecondaryPresence of Adverse Events as a Measure of Safety and Tolerability of Durvalumab Alone and in Combination With Novel Agents

The secondary endpoint of safety as assessed by the presence of adverse events and serious adverse events

Time frame:
From time of signature of informed consent up to 15 months post the first dose of study treatment
Reported as:
Count of participants · Participants
Presence of Adverse Events as a Measure of Safety and Tolerability of Durvalumab Alone and in Combination With Novel Agents
ParticipantsControl Arm (Durvalumab Monotherapy)Arm A (Durvalumab + Oleclumab)Arm B (Durvalumab + Monalizumab)
Participants with any TEAEs655761
Participants with any serious TEAEs232017
SecondaryPresence of Clinically Significant Laboratory Values as a Measure of Safety and Tolerability of Durvalumab Alone and in Combination With Novel Agents

The secondary endpoint of safety as assessed by the presence of Grade 3 or 4 clinical laboratory toxicities (based on NCI-CTCAE v5.0) in chemistry and hematology values

Time frame:
From baseline up to 15 months post the first dose of study treatment
Reported as:
Count of participants · Participants
Presence of Clinically Significant Laboratory Values as a Measure of Safety and Tolerability of Durvalumab Alone and in Combination With Novel Agents
ParticipantsControl Arm (Durvalumab Monotherapy)Arm A (Durvalumab + Oleclumab)Arm B (Durvalumab + Monalizumab)
Participants with any Grade 3 or 4 Alanine Aminostransferase (U/L) toxicities100
Participants with any Grade 3 or 4 Albumin (g/dL) toxicities200
Participants with any Grade 3 or 4 Amylase (U/L) toxicities102
Participants with any Grade 3 or 4 Aspartate Aminotransferase (U/L) toxicities101
Participants with any Grade 3 or 4 Creatinine (mg/dL) toxicities100
Participants with any Grade 3 or 4 Creatinine Clearance Rate (mL/min) toxicities210
Participants with any Grade 3 or 4 Gamma Glutamyl Transferase (U/L) toxicities100
Participants with any Grade 3 or 4 Hyperkalemia (mEq/L) toxicities002
Participants with any Grade 3 or 4 Hypokalemia (mEq/L) toxicities101
Participants with any Grade 3 or 4 Hypocalcemia (corrected) (mg/dL) toxicities100
Participants with any Grade 3 or 4 Hypernatremia (mEq/L) toxicities121
Participants with any Grade 3 or 4 Lipase (U/L) toxicities142
Participants with any Grade 3 or 4 Hemoglobin increased (g/dL) toxicities300
Participants with any Grade 3 or 4 Lymphocyte count increased (10^3/uL) toxicities191111
Participants with any Grade 3 or 4 Platelet count decreased (10^3/uL) toxicities100
SecondaryPresence of Abnormalities in Vital Signs as a Measure of Safety and Tolerability of Durvalumab Alone and in Combination With Novel Agents

The secondary endpoint of safety as assessed by the presence of abnormal vital signs reported as adverse events

Time frame:
From baseline up to 15 months post the first dose of study treatment
Reported as:
Count of participants · Participants
Presence of Abnormalities in Vital Signs as a Measure of Safety and Tolerability of Durvalumab Alone and in Combination With Novel Agents
ParticipantsControl Arm (Durvalumab Monotherapy)Arm A (Durvalumab + Oleclumab)Arm B (Durvalumab + Monalizumab)
Hypertension330
Hypotension203
Palpitations001
Pyrexia6810
Tachycardia122
SecondaryDuration of Response (DoR) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents

The duration from the first documentation of a subsequently confirmed OR to the first documentation of a disease progression according to RECIST v1.1 or death due to any cause, whichever occurs first. Only participants who have achieved OR (confirmed CR or confirmed PR) will be evaluated for DoR

Time frame:
Up to approximately 54 months (through the database cutoff date of 18-Jul-2023).
Reported as:
Median · Months
Duration of Response (DoR) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents
MonthsControl Arm (Durvalumab Monotherapy)Arm A (Durvalumab + Oleclumab)Arm B (Durvalumab + Monalizumab)
Duration of Response (DoR) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel AgentsNA (14.1 to NA)29.9 (17.1 to NA)23.0 (10.2 to NA)
SecondaryDisease Control (DC) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents

Disease control rate (DCR) was defined as the percentage of participants with a BOR of confirmed CR, confirmed PR, or SD (maintained for ≥ 16 weeks) based on RECIST v1.1.

Time frame:
Up to approximately 54 months (through the database cutoff date of 18-Jul-2023).
Reported as:
Number · Percentage of Participants
Disease Control (DC) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents
Percentage of ParticipantsControl Arm (Durvalumab Monotherapy)Arm A (Durvalumab + Oleclumab)Arm B (Durvalumab + Monalizumab)
Disease Control (DC) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents58.2 (45.5 to 70.2)80.0 (67.7 to 89.2)79.0 (66.8 to 88.3)
SecondaryProgression-Free Survival (PFS) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents

PFS was defined as the time from randomization until the first documentation of disease progression according to RECIST v1.1 or death due to any cause, whichever occurs first

Time frame:
Up to approximately 54 months (through the database cutoff date of 18-Jul-2023).
Reported as:
Median · Months
Progression-Free Survival (PFS) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents
MonthsControl Arm (Durvalumab Monotherapy)Arm A (Durvalumab + Oleclumab)Arm B (Durvalumab + Monalizumab)
Progression-Free Survival (PFS) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents7.3 (4.0 to 13.8)21.1 (10.4 to 30.9)19.8 (13.6 to 31.3)
SecondaryProgression-Free Survival 12 Month Landmark Rate (PFS-12) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents

PFS-12 was defined as the percentage of participants who were alive and progression free at 12 months after randomization.

Time frame:
PFS rate at 12 months after randomization.
Reported as:
Number · Percentage of Participants
Progression-Free Survival 12 Month Landmark Rate (PFS-12) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents
Percentage of ParticipantsControl Arm (Durvalumab Monotherapy)Arm A (Durvalumab + Oleclumab)Arm B (Durvalumab + Monalizumab)
Progression-Free Survival 12 Month Landmark Rate (PFS-12) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents37.6 (24.7 to 50.4)63.5 (49.2 to 74.7)73.2 (59.6 to 82.9)
SecondaryOverall Survival (OS) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents

OS was defined as the time from the date of randomization until death due to any cause.

Time frame:
From time of randomization until death due to any cause. Assessed through the database cutoff date of 18-Jul-2023).
Reported as:
Median · Months
Overall Survival (OS) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents
MonthsControl Arm (Durvalumab Monotherapy)Arm A (Durvalumab + Oleclumab)Arm B (Durvalumab + Monalizumab)
Overall Survival (OS) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents40.9 (22.6 to NA)NA (31.9 to NA)NA (31.3 to NA)
SecondaryPharmacokinetics of Durvalumab Alone and in Combination With Novel Agents

Geometric mean serum concentrations of durvalumab (μg/mL) were reported for each time point where data warrant, as appropriate.

Time frame:
From randomization up to 15 months after first treatment: Cycle 1 Day 1 pre-dose and at end of infusion, Cycle 2 Day 1 pre-dose (1 month), Cycle 7 Day 1 pre-dose (6 months), Cycle 11 Day 1 pre-dose (10 months) and 15 months post Cycle 1 Day 1
Reported as:
Geometric mean · Micrograms per milliliter
Pharmacokinetics of Durvalumab Alone and in Combination With Novel Agents
Micrograms per milliliterControl Arm (Durvalumab Monotherapy)Arm A (Durvalumab + Oleclumab)Arm B (Durvalumab + Monalizumab)
Cycle 1 Day 1: End of Infusion318.0 ± 199.6277.4 ± 316.1223.7 ± 1272
Cycle 2 Day 1: Pre-Dose59.7 ± 58.668.0 ± 49.974.3 ± 40.7
Cycle 7 Day 1: Pre-Dose151.6 ± 37.7127.9 ± 66.4176.5 ± 45.6
Cycle 11 Day 1: Pre-Dose156.7 ± 50.0146.5 ± 91.3172.4 ± 40.4
SecondaryPharmacokinetics of Novel Agents in Combination With Durvalumab

Geometric mean serum concentrations of oleclumab (μg/mL) and monalizumab (μg/mL) were reported for each time point where data warrant, as appropriate.

Time frame:
From randomization up to 15 months after first treatment: Cycle 1 Day 1 pre-dose and at end of infusion, Cycle 2 Day 1 pre-dose (1 month), Cycle 7 Day 1 pre-dose (6 months), Cycle 11 Day 1 pre-dose (10 months) and 15 months post Cycle 1 Day 1
Reported as:
Geometric mean · Micrograms per milliliter
Pharmacokinetics of Novel Agents in Combination With Durvalumab
Micrograms per milliliterArm A (Durvalumab + Oleclumab)Arm B (Durvalumab + Monalizumab)
Cycle 1 Day 1: End of Infusion581.6 ± 210.5160.0 ± 286.4
Cycle 2 Day 1: Pre-Dose216.4 ± 58.6102.6 ± 39.2
Cycle 7 Day 1: Pre-Dose124.5 ± 109.0194.5 ± 33.8
Cycle 11 Day 1: Pre-Dose132.0 ± 166.8196.2 ± 48.7
SecondaryPresence of Detectable Anti-Drug Antibody (ADA) Response to Durvalumab Alone and in Combination With Novel Agents

ADA prevalence was defined as the percentage of participants with positive ADA result at any time, baseline or post-baseline. ADA positive post-baseline only was also referred to as treatment-induced ADA positive. Treatment-boosted ADA was defined as baseline positive ADA titer that was boosted to a 4-fold or higher following drug administration. Persistently positive was defined as positive at ≥2 post-baseline assessments (with ≥16 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive was defined as having at least 1 post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive. ADA incidence (treatment-emergent ADA positive) was defined as the sum of treatment-induced ADA and treatment-boosted ADA.

Time frame:
From randomization up to 15 months after first treatment: Cycle 1 Day 1 pre-dose, Cycle 2 Day 1 pre-dose (1 month), Cycle 7 Day 1 pre-dose (6 months), Cycle 11 Day 1 pre-dose (10 months) and 15 months post Cycle 1 Day 1
Reported as:
Count of participants · Participants
Presence of Detectable Anti-Drug Antibody (ADA) Response to Durvalumab Alone and in Combination With Novel Agents
ParticipantsControl Arm (Durvalumab Monotherapy)Arm A (Durvalumab + Oleclumab)Arm B (Durvalumab + Monalizumab)
ADA positive at any visit (ADA prevalence)312
Treatment-emergent ADA positive (ADA incidence)100
Treatment-boosted ADA000
Treatment-induced ADA (positive post-baseline only)100
ADA positive at baseline only212
ADA positive post-baseline and positive at baseline000
Persistently positive100
Transiently positive000
SecondaryPresence of Detectable Anti-Drug Antibody (ADA) Response to Novel Agents in Combination With Durvalumab

ADA prevalence was defined as the percentage of participants with positive ADA result at any time, baseline or post-baseline. ADA positive post-baseline only was also referred to as treatment-induced ADA positive. Treatment-boosted ADA was defined as baseline positive ADA titer that was boosted to a 4-fold or higher following drug administration. Persistently positive was defined as positive at ≥2 post-baseline assessments (with ≥16 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive was defined as having at least 1 post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive. ADA incidence (treatment-emergent ADA positive) was defined as the sum of treatment-induced ADA and treatment-boosted ADA.

Time frame:
From randomization up to 15 months after first treatment: Cycle 1 Day 1 pre-dose, Cycle 2 Day 1 pre-dose (1 month), Cycle 7 Day 1 pre-dose (6 months), Cycle 11 Day 1 pre-dose (10 months) and 15 months post Cycle 1 Day 1
Reported as:
Count of participants · Participants
Presence of Detectable Anti-Drug Antibody (ADA) Response to Novel Agents in Combination With Durvalumab
ParticipantsArm A (Durvalumab + Oleclumab)Arm B (Durvalumab + Monalizumab)
ADA positive at any visit (ADA prevalence)01
Treatment-emergent ADA positive (ADA incidence)01
Treatment-boosted ADA00
Treatment-induced ADA (positive post-baseline only)01
ADA positive at baseline only00
ADA positive post-baseline and positive at baseline00
Persistently positive00
Transiently positive01

Adverse events

Collected over AEs and SAEs were collected from time of signature of informed consent up to 15 months post the first dose of study treatment. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Durvalumab Monotherapy27/66 (40.9%)23/66 (34.8%)61/66 (92.4%)
Durvalumab + Oleclumab23/59 (39%)20/59 (33.9%)52/59 (88.1%)
Durvalumab + Monalizumab24/61 (39.3%)17/61 (27.9%)58/61 (95.1%)
Most frequent serious events
Showing 10 of 56
Most frequent serious events
EventDurvalumab MonotherapyDurvalumab + OleclumabDurvalumab + Monalizumab
PneumonitisRespiratory, thoracic and mediastinal disorders3/666/592/61
PneumoniaInfections and infestations5/664/590/61
Radiation pneumonitisInjury, poisoning and procedural complications1/662/590/61
SeizureNervous system disorders2/660/590/61
Acute respiratory failureRespiratory, thoracic and mediastinal disorders2/660/591/61
Pleural effusionRespiratory, thoracic and mediastinal disorders2/661/590/61
PyrexiaGeneral disorders0/661/591/61
Sudden deathGeneral disorders0/661/590/61
AppendicitisInfections and infestations0/661/590/61
Enterocolitis infectiousInfections and infestations0/661/590/61
Most frequent other events
Showing 10 of 55
Most frequent other events
EventDurvalumab MonotherapyDurvalumab + OleclumabDurvalumab + Monalizumab
CoughRespiratory, thoracic and mediastinal disorders11/6619/5926/61
DyspnoeaRespiratory, thoracic and mediastinal disorders17/6615/5914/61
PruritusSkin and subcutaneous tissue disorders7/6610/5915/61
AstheniaGeneral disorders10/6611/5915/61
HypothyroidismEndocrine disorders10/668/5913/61
DiarrhoeaGastrointestinal disorders7/668/5913/61
ArthralgiaMusculoskeletal and connective tissue disorders11/6610/5911/61
RashSkin and subcutaneous tissue disorders6/669/598/61
ConstipationGastrointestinal disorders10/664/592/61
PyrexiaGeneral disorders6/667/599/61

Baseline characteristics

The Intent-to-treat (ITT) population included participants who were randomized and were analyzed according to their randomized treatment group

Age, Continuous
Age, Continuous(years)Control Arm (Durvalumab Monotherapy)Arm A (Durvalumab + Oleclumab)Arm B (Durvalumab + Monalizumab)Total
Mean65.5 ± 8.963.8 ± 9.564.4 ± 9.264.6 ± 9.2
Sex: Female, Male
Sex: Female, Male(Participants)Control Arm (Durvalumab Monotherapy)Arm A (Durvalumab + Oleclumab)Arm B (Durvalumab + Monalizumab)Total
Female22182060
Male454242129
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Control Arm (Durvalumab Monotherapy)Arm A (Durvalumab + Oleclumab)Arm B (Durvalumab + Monalizumab)Total
Hispanic or Latino3328
Not Hispanic or Latino635659178
Unknown or Not Reported1113
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Control Arm (Durvalumab Monotherapy)Arm A (Durvalumab + Oleclumab)Arm B (Durvalumab + Monalizumab)Total
American Indian or Alaska Native0101
Asian54514
Black or African American1528
Native Hawaiian or Other Pacific Islander1001
White574755159
Other1203
Missing2103
Region of Enrollment
Region of Enrollment(Participants)Control Arm (Durvalumab Monotherapy)Arm A (Durvalumab + Oleclumab)Arm B (Durvalumab + Monalizumab)Total
Canada3216
France1519539
Hong-Kong1236
Italy0336
Portugal3036
Spain19122253
Taiwan1012
United States25222471
08

Study locations

73 sites
  • Research Site
    Anaheim, California 92801, United States
  • Research Site
    Duarte, California 91010, United States
  • Research Site
    Sacramento, California 95825, United States
  • Research Site
    New Haven, Connecticut 06510, United States
  • Research Site
    West Haven, Connecticut 06516, United States
  • Research Site
    Washington D.C., District of Columbia 20007, United States
  • Research Site
    Orlando, Florida 32804, United States
  • Research Site
    Winter Haven, Florida 33881, United States
  • Research Site
    Wichita, Kansas 67214, United States
  • Research Site
    Lexington, Kentucky 40503, United States
  • Research Site
    Louisville, Kentucky 40202, United States
  • Research Site
    Baton Rouge, Louisiana 70809, United States
  • Research Site
    Covington, Louisiana 70433, United States
  • Research Site
    Rosedale, Maryland 21237, United States
  • Research Site
    Lincoln, Nebraska 68510, United States
  • Research Site
    New York, New York 10029, United States
  • Research Site
    New York, New York 10065, United States
  • Research Site
    Portland, Oregon 97227-1191, United States
  • Research Site
    Gettysburg, Pennsylvania 17325, United States
  • Research Site
    Lancaster, Pennsylvania 17601, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Sioux Falls, South Dakota 57105, United States
  • Research Site
    Germantown, Tennessee 38138, United States
  • Research Site
    Memphis, Tennessee 38120, United States
  • Research Site
    Tyler, Texas 75701, United States
  • Research Site
    Salt Lake City, Utah 84112, United States
  • Research Site
    Richmond, Virginia 23230, United States
  • Research Site
    Tacoma, Washington 98405, United States
  • Research Site
    Edmonton, Alberta T6G 1Z2, Canada
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Montreal, Quebec H4A 3J1, Canada
  • Research Site
    Bordeaux, 33076, France
  • Research Site
    Brest, 29609, France
  • Research Site
    Bron, 69677, France
  • Research Site
    Créteil, 94010, France
  • Research Site
    La Rochelle, 17019, France
  • Research Site
    Lille, 59037, France
  • Research Site
    Limoges, 87042, France
  • Research Site
    Lyon, 69004, France
  • Research Site
    Marseille, 13015, France
  • Research Site
    Nice, 06189, France
  • Research Site
    Pierre-Bénite, 69495, France
  • Research Site
    Rennes, 35033, France
  • Research Site
    Strasbourg, 67065, France
  • Research Site
    Toulouse, 31059, France
  • Research Site
    Hong Kong, Hong Kong
  • Research Site
    Jordan, Hong Kong
  • Research Site
    Kowloon, Hong Kong
  • Research Site
    Catania, 95125, Italy
  • Research Site
    Cremona, 26100, Italy
  • Research Site
    Milan, 20132, Italy
  • Research Site
    Milan, 20133, Italy
  • Research Site
    Palermo, 90127, Italy
  • Research Site
    Ravenna, 48121, Italy
  • Research Site
    Siena, 53100, Italy
  • Research Site
    Gdynia, 81-519, Poland
  • Research Site
    Lodz, 90-153, Poland
  • Research Site
    Lodz, 90-242, Poland
  • Research Site
    Lisbon, 1400-038, Portugal
  • Research Site
    Lisbon, 1500-650, Portugal
  • Research Site
    Porto, 4099-001, Portugal
  • Research Site
    Porto, 4200-072, Portugal
  • Research Site
    A Coruña, 15006, Spain
  • Research Site
    Badajoz, 06008, Spain
  • Research Site
    Barcelona, 08035, Spain
  • Research Site
    Barcelona, 08041, Spain
  • Research Site
    Barcelona, 08916, Spain
  • Research Site
    Castellon, 12002, Spain
  • Research Site
    Madrid, 28034, Spain
  • Research Site
    Málaga, 29010, Spain
  • Research Site
    Valencia, 46014, Spain
  • Research Site
    Chiayi City, 61363, Taiwan
  • Research Site
    Taichung, 402, Taiwan
09

References and documents

Publications

  • Aggarwal C, Martinez-Marti A, Majem M, Barlesi F, Carcereny E, Chu Q, Monnet I, Sanchez-Hernandez A, Dakhil S, Camidge DR, Pillet M, Brown M, Paliompeis C, Dowson A, Cooper ZA, Kumar R, Herbst RS. Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non-Small Cell Lung Cancer: Update From the COAST Randomized Clinical Trial. JAMA Netw Open. 2025 Jul 1;8(7):e2518440. doi: 10.1001/jamanetworkopen.2025.18440. PubMed 40663352 ↗
  • Herbst RS, Majem M, Barlesi F, Carcereny E, Chu Q, Monnet I, Sanchez-Hernandez A, Dakhil S, Camidge DR, Winzer L, Soo-Hoo Y, Cooper ZA, Kumar R, Bothos J, Aggarwal C, Martinez-Marti A. COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022 Oct 10;40(29):3383-3393. doi: 10.1200/JCO.22.00227. Epub 2022 Apr 22. PubMed 35452273 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Jul 2023, 54 months.

Results were first posted in Oct 2024, 1 year 2 months after primary completion.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 54 months is above that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2018
First posted
Jan 30, 2019
StartActual
Dec 19, 2018
Primary completionActual
Jul 18, 2023
CompletionActual
Jul 18, 2023
Results first posted
Oct 8, 2024
Last update
Oct 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03822351
Lead sponsor
MedImmune LLC
Responsible party
Sponsor
First posted
Jan 30, 2019
Start date
Dec 19, 2018
Primary completion
Jul 18, 2023
Completion
Jul 18, 2023
Results posted
Oct 8, 2024
Last update
Oct 8, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Durvalumab · Oleclumab · Monalizumab

Start the discussion